Mark Fladrich
Chair

Mark is an experienced leader with over 30 years of experience in the pharmaceutical industry, specialising in commercial, strategic, and operational roles across a broad range of therapeutic areas, including pain management.

Most recently, Mark served as Chief Commercial Officer at Grunenthal, a privately owned German company with a strong presence in Europe and Latin America. During his time at the company, he expanded Grunenthal’s commercial presence into the US in parallel with the relaunch of a non-opioid chronic pain management treatment.

Prior to this, Mark spent 23 years at AstraZeneca, holding various senior roles, including Vice President of Global Strategic Marketing, Country President roles in Germany, Australia and New Zealand and Regional Head of Southern and Western Europe.

Mark has also held leadership roles at Allergan and Faulding Pharmaceuticals in Australia.

Currently, Mark is the Chair of the Strategic Advisory Board for Atacana, a global pharmaceutical and biotech industry consulting firm and serves as a Board Observer and Strategic Advisor at HealthMatch, a Sydney based digital startup who have developed a patient centric platform for clinical trial recruitment.

Leon Hoare
Non-Executive Director

Mr Hoare is an accomplished commercial leader with expertise across multiple Life Sciences sectors. Until December 2025, Mr Hoare served as Managing Director of Lohmann & Rauscher, Australia and New Zealand (ANZ), a privately held European medical device company, and led the establishment of its ANZ subsidiary.

Previously, he was Managing Director of Smith & Nephew (S&N) ANZ, one of S&N’s largest global subsidiaries outside the United States. During his 24 years with Smith & Nephew, Mr Hoare held multiple executive roles, including President of its Asia-Pacific Advanced Wound Management (AWM) businesses for five years. He was also one of three Regional Presidents on the AWM Global Executive Management team.

His career also includes a senior role at Bristol-Myers Squibb and as Vice Chair of the Medical Technology Association of Australia, Australia’s peak medical device industry body.

Mr Hoare is also the Chair of the People & Culture Committee.

Public company directorships in the past 3 years:
Polynovo Limited (since 27 January 2016), where he is the Chair of the board and Chair of the Nominations Committee.

Christine Emmanuel-Donnelly
Non-Executive Director

Christine is an experienced IP and business development professional having 35 years’ experience locally and internationally.

Christine is a former Executive Manager of Business Development and Commercial at the CSIRO, where she led the management of CSIRO’s IP team and IP portfolio for 14 years and managed the CSIRO equity portfolio for over 5 years.

Prior to this role, Christine was in-house IP Counsel for Unilever in the UK and practised as a patent and trademark attorney for Wilson Gunn (UK), Davies Collison Cave and Griffith Hack in Melbourne.

Christine is also currently chairwoman of Impedimed Ltd and non-executive director of Polynovo Ltd, Pikcha Holdings Ltd, trading as Seminal. She was previously on the Board of the Institute of Patent & Trademarks Attorneys of Australia for 13 years.

Public company directorships in the past 3 years:
Polynovo Limited since 13 May 2020
Impedimed Limited since 2023

Russell Basser
Non-Executive Director

Russell is a qualified physician, with over 30 years of international medical and biopharmaceutical experience. He has worked as a medical oncologist in Melbourne prior to joining CSL in 2001.

During his 21 years at CSL, Russell held multiple global executive roles, including Head of Global Clinical Development, Chief Medical Officer and Senior VP of Research and Development for CSL Seqirus. He has substantial expertise in international drug and vaccine development and spent several years based in the USA.

Russell currently serves as a non-executive director on the Boards of Starpharma Holdings Limited and Doherty Clinical Trials. He has previously served on the Board of the ANZ Breast Cancer Trials Group and the Hadassah Australia Medical Research Collaboration.

Paul Townsend
Non-Executive Director

Paul is an experienced global finance executive with a strong commercial focus and reputation of delivering results across diverse industries, including manufacturing, resources, consumer products and academia.

Paul has substantial ASX CFO experience at organisations including Nufarm, Asaleo Care, and Pacific Hydro, as well as Monash University, bringing a wealth of knowledge to MDI.

His extensive track record includes business turnarounds, new venture start-ups, mergers and acquisitions across local and global markets, navigating equity and debt capital markets and implementing changes necessary to deliver strong earnings growth, robust cash flow, and balance sheet optimisation.

Paul’s strategic mindset and leadership have consistently enabled successful business outcomes and the generation of long-term value. Paul has a Bachelor of Business (Accounting), FCA and GAICD.